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Abstract
Backgrounds: VonWillebrand disease (VWD) is reportedly the most common inherited
bleeding disorder and can also arise as an acquired syndrome (AVWS). These
disorders arise due to defects and/or deficiency of the plasma protein von Willebrand
factor (VWF). High plasma VWF concentrations have been reported in patients with
various types of cancer, such as prostatic cancer. Metastasization may be associated
with activation of hemostatic processes resulting in increased levels of circulating
factor VIII-related antigen (FVIIIRAg) (von Willebrand factor antigen).
Objective: To evaluate the status of VWF antigen in Sudanese patients with prostate
cancer attending RICK hospital.
Methods: This is a cross-sectional study carried out in Khartoum state at Khartoum
oncology (RICK) hospital, during the period from April to June 2018, 45 samples were
collected from patients with non-metastatic CA prostate, their ages ranged from 51
to 82 yr. The VWF level was measured using Enzyme-linked immunosorbent assay
(ELISA). Data were analyzed by the statistical package for social science (SPSS).
Results: Serology for VWF antigenwas done for 45 cases of prostate cancer. According
to the age, 2 (8%) patients with age 51–66 yr had a high concentration of VWF, while
24 (92%) had normal VWF antigen concentration; of those with age 67–82 yr, 4 (21%)
had high VWF antigen and 15 (79%) had normal antigen.
Conclusion: The study revealed that more than 80% of Sudanese patients with non-
metastatic prostate cancer have a normal concentration of VWF.
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1. Introduction
The glycoprotein von Willebrand factor (VWF) mediates the adhesion of platelets to
subendothelial surfaces in primary hemostasis in case of vascular injury [1]. Plasma
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VWF levels vary over a very broad range extending from 40 to 240% of the mean value
[2]. A major determinant of plasma VWF levels is the ABO blood group, but several
clinical conditions, such as myocardial infarction, diabetes mellitus, liver disease, and
acute infections, induce increased plasma VWF concentrations [3–8]. There are some
studies describing a correlation of VWF with different cancers like prostate cancer,
cervical and ovarian cancer, head and neck cancer, larynx cancer, and colorectal cancer
(CRC) [9–15]. Experimental models favor the hypothesis that VWF connects tumor cells
to platelets and so assists during the pathogenesis of metastases. It is supposed that
these VWF-tumor-cell-emboli are hardly detected by the immune system [16–18]. As
VWF levels increase with progressive disease [14, 15], it is considered as a potential
clinical marker in CRC. Metastasizing may be associated with activation of hemostatic
processes resulting in increased levels of circulating von Willebrand factor antigen.
The objective of this study was to evaluate the status of VWF Ag in Sudanese patients
with non-metastatic prostate cancer attending RICK.
2. Methods
This is a retrospective cross-sectional study in which a total of 45 (non-metastatic) PC
patients were recruited at the RICK hospital, in the period from April to June 2018.
A venous blood sample (3 ml) was taken from each subject into a tube containing
3.8% trisodium citrate, platelet poor plasma was prepared and used for the assessment
of VWF level. The VWF level was measured using Enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions (TECHNOZYM, Austria).
2.1. Ethical consideration
Ethical clearance was obtained from the Institutional Review Board at Al Neelain Univer-
sity. Principal investigator obtained written informed consent from all participants prior
to their inclusion in the study.
2.2. Data analysis
All obtained results were analyzed using Statistical Package for the Social Sciences
(SPSS) version 20.0, with Pearson’s chi-square test used to assess intergroup signifi-
cance and t-test used to determine differences in means, other variables frequencies
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and odd ratio calculated for comparison and presented in form of figures and tables.
P-value and odd ratio were used to assess the significance of the results.
3. Results and Discussion
High-plasma VWF concentrations have been reported in patients with several types
of cancers, such as prostatic cancer head and neck and laryngeal cancer, probably
representing an acute phase reactant. In the present study, we evaluated the status of
VWF antigen (VWF:Ag) in 45 patients diagnosed with prostate cancer (non-metastatic).
Their mean age was 66.5 yr, 26/45 (58/%) patients were 51–66 years old, and 19/45
(42%) were 67–82 Years old. The patient’s marital status: 34/54 (76%) of them were
married and 11/45 (24%) were unmarried; 12/45 (27%) patients had hypertension and
4/45 (9%) had diabetes mellitus. Serology for VWF antigen was done in 45 cases of
prostate cancer. According to the age, 2 (8%) with age 51–66 yr had high concentration
of VWF, 24 (92%) with same age had normal VWF antigen, and those with age 67–82
yr, 4 (21%) with high VWF antigen and 15 (79%) with normal antigen. In association with
marital status: 5 (15%) of the married patients had high VWF antigen and 29 (85%) were
normal. In unmarried men, 1 (9%) was found to have high Ag level and 10 (91%) with
normal Ag level. In association with hypertension and diabetes mellites, 2 (17%) of the
hyper-tensive patients had high antigen and 10 (83%) had normal antigen concentration.
Among the non-hypertensive patients, 4 (12%) had high concentration and the other 29
(88%) had normal Ag concentration. Of the diabetic patients, 4 (100%) had normal antigen
concentration and among the non-diabetic patients, 6 (15%) had high concentration and
other 35 (85%) had normal value.
4. Conclusion
The study revealed that more than 80% of Sudanese patients with non-metastatic
prostate cancer presented with a normal concentration of VWF.
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Table 1: Demographic and clinical data in the population study.
Variables Frequency Percentage (%)
Age
51–66 Years 26 58











Figure 1: Distribution of Von Willebrand factor antigen in Sudanese Prostate Cancer patients.
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